HRTX vs PACB vs PCRX vs ACRS vs JAZZ

For growth investors, Heron Therapeutics, Inc.

(HRTX) is the stronger pick with 7. 4% revenue growth year-over-year, versus -58. 2% for Aclaris Therapeutics, Inc. (ACRS). Pacira BioSciences, Inc. (PCRX) offers the better valuation at 147. 8x trailing P/E (8. 6x forward), making it the more compelling value choice. Analysts rate Heron Therapeutics, Inc. (HRTX) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Pacira BioSciences, Inc.

is actually cheaper at 8. 6x.

Over the past 5 years, Jazz Pharmaceuticals plc (JAZZ) delivered a total return of +30.

0%, compared to -93. 4% for Pacific Biosciences of California, Inc. (PACB). Over 10 years, the gap is even starker: JAZZ returned +53. 7% versus HRTX's -92. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Aclaris Therapeutics, Inc.

(ACRS) is the lower-risk stock at 0. 30β versus Pacific Biosciences of California, Inc. 's 2. 43β — meaning PACB is approximately 701% more volatile than ACRS relative to the S&P 500. On balance sheet safety, Pacira BioSciences, Inc. (PCRX) carries a lower debt/equity ratio of 66% versus 142% for Pacific Biosciences of California, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Heron Therapeutics, Inc.

(HRTX) is pulling ahead at 7. 4% versus -58. 2% for Aclaris Therapeutics, Inc. (ACRS). On earnings-per-share growth, the picture is similar: Pacira BioSciences, Inc. grew EPS 107. 4% year-over-year, compared to -167. 5% for Jazz Pharmaceuticals plc. Over a 3-year CAGR, HRTX leads at 12. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pacira BioSciences, Inc.

(PCRX) is the more profitable company, earning 1. 0% net margin versus -829. 6% for Aclaris Therapeutics, Inc. — meaning it keeps 1. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JAZZ leads at 5. 3% versus -975. 9% for ACRS. At the gross margin level — before operating expenses — JAZZ leads at 88. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Pacira BioSciences, Inc.

(PCRX) trades at 8. 6x forward P/E versus 9. 4x for Jazz Pharmaceuticals plc — 0. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HRTX: 437. 9% to $6. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Aclaris Therapeutics, Inc.

(ACRS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 30)). Pacific Biosciences of California, Inc. (PACB) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACRS: -76. 3%, PACB: -81. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.